Aspire Biopharma Holdings, INC. (ASBPW) — SEC Filings

Overview

Aspire Biopharma Holdings, INC. (ASBPW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 3, 2025: Aspire Biopharma Holdings, Inc. (ASBPW) filed an S-1 on December 3, 2025, primarily for the resale of up to 41,500,000 shares of common stock by Arena Business Solutions Global SPC II, LTD. This includes 36,377,150 ELOC Shares, 5,000,000 Commitment Fee Shares, and 122,850 Transaction Fee Shares, all

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 7 bearish, 38 neutral. The dominant filing sentiment for Aspire Biopharma Holdings, INC. is neutral.

Filing Type Overview

Aspire Biopharma Holdings, INC. (ASBPW) has filed 4 S-1, 3 10-Q/A, 24 8-K, 2 DEF 14A, 4 10-Q, 2 10-K, 5 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (45)

• Aspire Biopharma Files S-1 for 41.5M Share Resale, Eyes $100M ELOC Funding — S-1 · Dec 3, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. (ASBPW) filed an S-1 on December 3, 2025, primarily for the resale of up to 41,500,000 shares of common stock by Arena Business
• Aspire Biopharma's Net Loss Explodes to $19.8M Amidst Reverse Acquisition — 10-Q/A · Nov 14, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. (ASBPW) reported a significant net loss of $19,773,114 for the nine months ended September 30, 2025, a substantial increase from
• Aspire Biopharma Holdings Files 8-K on Shareholder Vote — 8-K · Nov 5, 2025 Risk: low
  Aspire Biopharma Holdings, Inc. filed an 8-K on November 5, 2025, reporting on a submission of matters to a vote of security holders that occurred on November 4
• Aspire Biopharma Faces Delisting Notice — 8-K · Oct 17, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. filed an 8-K on October 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing als
• Aspire Biopharma Files 8-K: Equity Sales & Accountant Change — 8-K · Sep 26, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. filed an 8-K on September 26, 2025, reporting on unregistered sales of equity securities and changes in its certifying accountan
• Aspire Biopharma Seeks Reverse Split, Note Conversion Approval — DEF 14A · Sep 23, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. (ASBPW) is seeking stockholder approval for a reverse stock split and the issuance of shares related to convertible promissory n
• Aspire Biopharma Registers 147M Shares for Resale, Seeks Reverse Split Nod — S-1 · Sep 18, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. (ASBPW) filed an S-1 on September 18, 2025, to register the resale of up to 147,177,424 shares of common stock underlying Conver
• Aspire Biopharma Files 8-K for Material Agreement — 8-K · Aug 22, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. filed an 8-K on August 22, 2025, reporting a material definitive agreement entered into on August 19, 2025. The filing also incl
• Aspire Biopharma Restates Q1, Reveals $1M Liability Error — 10-Q/A · Aug 13, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. (ASBPW) filed a 10-Q/A to restate its Q1 2025 financial statements, correcting an understatement of liabilities and an overstate
• Aspire Biopharma Announces Board and Compensation Changes — 8-K · Jul 30, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. announced on July 24, 2025, a change in its board of directors and executive compensation arrangements. The filing details the d
• Aspire Biopharma Files 8-K, Formerly PowerUp Acquisition Corp. — 8-K · Jun 18, 2025 Risk: low
  Aspire Biopharma Holdings, Inc. filed an 8-K on June 18, 2025, reporting on events that occurred on June 17, 2025. The filing primarily concerns "Other Events"
• Aspire Biopharma Files 8-K: Director Changes & Officer Appointments — 8-K · Jun 10, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. filed an 8-K on June 10, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and
• Aspire Biopharma Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as PowerUp Acquisition Corp., is in
• Aspire Biopharma Files S-1 for Public Offering — S-1 · May 13, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. filed an S-1 form on May 13, 2025, indicating its intention to become a publicly traded company. The company, previously known a
• Aspire Biopharma Enters Material Definitive Agreement — 8-K · Apr 30, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. entered into a material definitive agreement on April 24, 2025. The filing also includes financial statements and exhibits relat
• Aspire Biopharma Faces Delisting Notice — 8-K · Apr 18, 2025 Risk: high
  Aspire Biopharma Holdings, Inc. filed an 8-K on April 18, 2025, to report its notice of delisting or failure to satisfy a continued listing rule. The company wa
• Aspire Biopharma Files S-1 for Securities Registration — S-1 · Apr 9, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. filed an S-1 form on April 9, 2025, to register securities. The company, previously known as PowerUp Acquisition Corp., is incor
• Aspire Biopharma Files 2024 10-K — 10-K · Apr 7, 2025 Risk: low
  Aspire Biopharma Holdings, Inc. filed its 2024 10-K on April 7, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Powe
• Aspire Biopharma Holdings, Inc. Files 8-K with Multiple Material Events — 8-K · Feb 21, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. (formerly PowerUp Acquisition Corp.) filed an 8-K on February 21, 2025, detailing several material events. These include enterin
• Aspire Biopharma Announces Material Agreement & Equity Sales — 8-K · Feb 20, 2025 Risk: medium
  Aspire Biopharma Holdings, Inc. announced on February 13, 2025, the entry into a material definitive agreement. The company also reported the creation of a dire
• PowerUp Acquisition Corp. Files 8-K on Shareholder Vote and Financials — 8-K · Feb 10, 2025 Risk: low
  PowerUp Acquisition Corp. filed an 8-K on February 10, 2025, reporting events as of February 4, 2025. The filing primarily concerns the submission of matters to
• PowerUp Acquisition Corp. Files 8-K for Material Agreement — 8-K · Dec 26, 2024 Risk: medium
  PowerUp Acquisition Corp. filed an 8-K on December 26, 2024, reporting a material definitive agreement entered into on December 18, 2024. The filing also covers
• 10-Q Filing — 10-Q · Nov 14, 2024
• PowerUp Acquisition Corp. Files 10-Q/A for Q1 2024 — 10-Q/A · Oct 24, 2024 Risk: low
  PowerUp Acquisition Corp. filed an amendment (10-Q/A) on October 24, 2024, for the quarterly period ended March 31, 2024. The company, previously named PowsedrU
• PowerUp Acquisition Corp. Signs Material Definitive Agreement — 8-K · Oct 10, 2024 Risk: medium
  PowerUp Acquisition Corp. entered into a material definitive agreement on October 9, 2024. The filing also includes financial statements and exhibits related to
• PowerUp Acquisition Corp. Signs Material Definitive Agreement — 8-K · Oct 4, 2024 Risk: medium
  PowerUp Acquisition Corp. entered into a material definitive agreement on October 2, 2024. The filing also includes financial statements and exhibits related to
• PowerUp Acquisition Corp. Files 8-K for Definitive Agreement — 8-K · Sep 6, 2024 Risk: medium
  PowerUp Acquisition Corp. filed an 8-K on September 6, 2024, reporting the entry into a material definitive agreement. The filing also includes financial statem
• PowerUp Acquisition Corp. Files 8-K — 8-K · Sep 3, 2024 Risk: low
  PowerUp Acquisition Corp. filed an 8-K on September 3, 2024, reporting other events and financial statements. The company, formerly known as PowsedrUp Acquisiti
• PowerUp Acquisition Corp. Signs Material Definitive Agreement — 8-K · Aug 30, 2024 Risk: medium
  PowerUp Acquisition Corp. entered into a material definitive agreement on August 26, 2024. The filing does not specify the other party or the nature of the agre
• PowerUp Acquisition Corp. Files Q2 2024 10-Q — 10-Q · Aug 16, 2024 Risk: low
  PowerUp Acquisition Corp. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as PowsedrUp Acquisition Corp., is involved in the pha
• SC 13G/A Filing — SC 13G/A · Jul 30, 2024
• PowerUp Acquisition Corp. Terminates Material Agreement — 8-K · Jul 23, 2024 Risk: medium
  PowerUp Acquisition Corp. filed an 8-K on July 23, 2024, reporting the termination of a material definitive agreement as of July 19, 2024. The filing also inclu
• PowerUp Acquisition Corp. Signs Material Definitive Agreement — 8-K · Jun 7, 2024 Risk: low
  PowerUp Acquisition Corp. entered into a material definitive agreement on June 6, 2024. The company, formerly known as PowsedrUp Acquisition Corp., is incorpora
• PowerUp Acquisition Corp. Files Q1 2024 10-Q — 10-Q · Jun 5, 2024 Risk: low
  PowerUp Acquisition Corp. filed its 10-Q for the period ending March 31, 2024. The company, formerly known as PowsedrUp Acquisition Corp., is involved in the ph
• SC 13G Filing — SC 13G · May 28, 2024
• PowerUp Acquisition Corp. Files 8-K on Shareholder Vote & Bylaws — 8-K · May 28, 2024 Risk: low
  PowerUp Acquisition Corp. filed an 8-K on May 28, 2024, reporting on matters submitted to a vote of security holders and amendments to its articles of incorpora
• PowerUp Acquisition Corp. Files 8-K for Material Agreement — 8-K · May 22, 2024 Risk: medium
  PowerUp Acquisition Corp. filed an 8-K on May 22, 2024, to report the entry into a material definitive agreement. The filing also includes financial statements
• PowerUp Acquisition Corp. Files 8-K — 8-K · May 20, 2024 Risk: medium
  PowerUp Acquisition Corp. filed an 8-K on May 20, 2024, reporting the entry into a material definitive agreement. The filing also includes other events and fina
• PowerUp Acquisition Corp. Files 8-K — 8-K · May 16, 2024 Risk: low
  PowerUp Acquisition Corp. filed an 8-K on May 16, 2024, reporting other events and financial statements. The company, incorporated in the Cayman Islands, is inv
• PowerUp Acquisition Corp. Schedules Extraordinary General Meeting for May 17, 2024 — DEF 14A · May 1, 2024 Risk: medium
  PowerUp Acquisition Corp. (ASBPW) filed a Proxy Statement (DEF 14A) with the SEC on May 1, 2024. PowerUp Acquisition Corp. will hold an extraordinary general me
• PowerUp Acquisition Corp. Files 2023 Annual Report — 10-K · Mar 11, 2024 Risk: low
  PowerUp Acquisition Corp. (ASBPW) filed a Annual Report (10-K) with the SEC on March 11, 2024. PowerUp Acquisition Corp. filed its 10-K report for the fiscal ye
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Saba Capital Amends PowerUp Acquisition Corp. (PWUP) Stake — SC 13G/A · Feb 8, 2024 Risk: low
  Saba Capital Management, L.P. filed an amended Schedule 13G/A on February 8, 2024, indicating their ownership of PowerUp Acquisition Corp. (ticker: PWUP) common
• Adage Capital Partners Amends PowerUp Acquisition Corp. Stake — SC 13G/A · Feb 7, 2024
  Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, indicating their ownership of Class A Ordinary Shares in PowerUp Acquisition Corp. (

Risk Profile

Risk Assessment: Of ASBPW's 39 recent filings, 7 were flagged as high-risk, 19 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Kraig T. Higginson
• Arthur S. Marcus, Esq.
• Stephen Quesenberry
• Kraig Higginson

Industry Context

Aspire Biopharma operates in the highly competitive and capital-intensive biopharmaceutical and supplements industry. The sector is characterized by long development cycles, significant regulatory hurdles, and the need for substantial funding. Companies often rely on novel delivery mechanisms, like Aspire's sublingual technology, to differentiate their products. The market for both prescription drugs and over-the-counter supplements is large but requires robust clinical evidence and effective marketing to succeed.

Top Tags

material-agreement (6) · Biopharma (5) · corporate-actions (4) · filing (4) · material-definitive-agreement (4) · definitive-agreement (4) · spac (4) · acquisition-corp (4) · Nasdaq Listing (3) · corporate-governance (3)

Key Numbers

• Shares for Resale: 41,500,000 — Total shares Arena Business Solutions Global SPC II, LTD may resell, indicating significant potential dilution.
• Potential ELOC Proceeds: $100,000,000 — Maximum proceeds Aspire Biopharma may receive from the sale of shares to Arena under the Second ELOC Agreement, crucial for funding operations.
• Common Stock Price: $0.099 — Closing sale price of ASBP common stock on December 1, 2025, highlighting the low valuation.
• Warrant Price: $0.0226 — Last closing price of ASBPW warrants on November 28, 2025.
• ELOC Shares: 36,377,150 — Shares that may be issued and sold to Arena pursuant to advance notices under the Second ELOC Agreement.
• Commitment Fee Shares: 5,000,000 — Shares issued to Arena as consideration for entering into the Second ELOC Agreement.
• Transaction Fee Shares: 122,850 — Shares issued to Arena as a transaction fee pursuant to the Second ELOC Agreement.
• Nasdaq Listing Date: February 20, 2025 — Date trading of common stock and warrants began on Nasdaq under ASBP and ASBPW.
• Second ELOC Agreement Date: November 11, 2025 — Date of the Purchase Agreement with Arena Business Solutions Global SPC II, LTD.
• Filing Date: December 3, 2025 — Date the S-1 registration statement was filed with the SEC.
• Net loss for nine months ended Sept 30, 2025: $19,773,114 — Significantly increased from $544,162 in 2024, indicating worsening financial performance.
• Net revenue for nine months ended Sept 30, 2025: $1,941 — First reported revenue, but extremely minimal, highlighting lack of commercialization.
• General and administrative expenses for nine months ended Sept 30, 2025: $15,982,233 — Massive increase from $410,805 in 2024, largely due to stock-based compensation.
• Stock-based compensation for nine months ended Sept 30, 2025: $14,131,250 — Major component of increased G&A expenses, impacting net loss.
• Accumulated deficit as of Sept 30, 2025: $22,550,347 — Indicates significant historical losses and negative equity.

Related Companies

ASBP · PWUP · PWUPU

Frequently Asked Questions